

10/530249 #2

JC06 Rec'd PCT/PTO 04 APR 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87291

Masahiko TERAKADO, et al.

Appln. No.: National Stage Entry of PCT/JP03/06680

Confirmation No.: not yet assigned

Group Art Unit: not yet assigned

Filed: April 04, 2005

Examiner: not yet assigned

For: LPA RECEPTOR ANTAGONIST

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10/530249

INFORMATION DISCLOSURE STATEMENT
National Stage Entry of PCT/JP03/06680

JC06 Rec'd PCT/PTO 04 APR 2005


filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, (International Search Report for PCT/JP03/06680 dated August 19, 2003), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,


Mark Boland
Registration No. 32,197

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 4, 2005

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	National Stage Entry of PCT/JP03/06680
				Confirmation Number	Not yet assigned
				Filing Date	April 04, 2005
				First Named Inventor	Masahiko TERAOKA
				Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet 1 of 1				Attorney Docket Number	Q87291

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
	/	WO	02/29001	A	4-11-2002	University of Virginian Patent Foundation	
	/	WO	95/12572	A1	5/11/1995	Abbott Laboratories	
	✓	EP	341,081	A1	8/11/1989	Ono Pharmaceutical Co., Ltd.	
	/	WO	93/12095	A1	6/24/1993	Pfizer Inc.	
	/	JP	56/90067	A	7/21/1981	Hokuriku Seiyaku Co., Ltd.	
	"	WO	02/62798	A1	8/15/2002	Dr. Reddy's Research Foundation	
		WO	99/8501	A1	2/25/1999	Dr. Reddy's Research Foundation	
		JP	11/158144	A	6/15/1999	SSP Co., Ltd.	
	/	JP	10/287634	A	10/27/1998	Otsuka Pharmaceutical Co., Ltd.	
	/	WO	02/646	A1	1/3/2002	Smithkline Beecham Corp.	
	/	WO	01/206	A1	1/4/2001	Daiichi Pharmaceutical Co., Ltd.	
	✓	EP	573271	A1	12/8/1993	Eli Lilly and Co.	
	/	EP	390215	A1	10/3/1990	Wakunaga Seiyaku Kabushik Kaisha	
		WO	02/62389	A1	8/15/2002	Ono Pharmaceutical Co., Ltd.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		International Search Report for PCT/JP03/06680 dated August 19, 2003	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.